Parameter
| Biomarker | MGMT Promoter Meth | Full name | MGMT Promoter Methylation | Molecular Type | DNA Methylation |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prediction, Prognosis |
| Disease | Glioblastoma | Disease Subtypes | / | ||
| Organ | Brain | Test Sample / Technology Platform | Tumor Tissue (Methylation-Specific PCR, Pyrosequencing, NGS) | ||
| Pathobiological Mechanisms | Methylation in the promoter region silences the MGMT gene, reduces O6-methylguanine DNA repair, and enhances temozolomide (TMZ) chemotherapy sensitivity. | ||||
| Clinical Availability Status | Clinically available | ||||
| Notes and Dynamics | The response rate to TMZ treatment is increased by 30%-50% in methylation-positive patients, and the median survival is extended to 15-18 months, a core basis for formulating clinical chemotherapy regimens. | ||||